Skip to main content

Clinical Trials Using Venetoclax

Review the clinical trials studying venetoclax on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 156

Venetoclax in Combination with Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Imetelstat and Azacitidine with or without Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, IMAGINE Trial
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Hyper-CVAD in Combination with Venetoclax for the Treatment of Pediatric, Adolescent and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CPX-351 With or Without Venetoclax in Treating Patients with Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Rezatapopt in Combination with Azacitidine with or without Venetoclax for the Treatment of TP53Y220C Mutant Relapsed, Refractory or Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Status: Active
Location: 3 locations
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
Status: Active
Location: See ClinicalTrials.gov
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
Status: Active
Location: See ClinicalTrials.gov
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and Lintuzumab-Ac225 in AML Patients
Status: Active
Location: See ClinicalTrials.gov
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Status: Active
Location: See ClinicalTrials.gov
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Status: Active
Location: See ClinicalTrials.gov
Universal Donor CD33 CAR Natural Killer Cells for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Approved
Location: Nationwide Children's Hospital, Columbus, Ohio
Ascorbate with Azacitidine and Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Status: Approved
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Dasatinib and Venetoclax in Treating Patients with Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and Ibrutinib in Treating Patients with Chronic or Small Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Comparing New Treatments for People with Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Status: Temporarily Closed to Accrual
Location: 86 locations
Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia
Status: Temporarily Closed to Accrual
Location: 9 locations
Ponatinib in Combination with Venetoclax and Mini-hyper CVD Chemotherapy for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Status: Temporarily Closed to Accrual
Location: 100 locations
Acalabrutinib, Venetoclax, and Obinutuzumab for the treatment of Relapsed or Refractory and Previously Untreated Mantle Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 4 locations
Venetoclax in Combination with Azacitidine followed by Donor Lymphocyte Infusion for the Treatment of Patients with Very High-Risk Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Venetoclax and Azacitidine or Chemotherapy for the Treatment of Hematologic Malignancies in Pediatric and Young Adult Patients
Status: Temporarily Closed to Accrual
Location: 6 locations